Key Facts
• On August 25, 2025, Terumo announced plans to acquire OrganOx for $1.5 billion.
• The acquisition aims for completion by March 2026, pending regulatory approvals in the US and Europe.
• OrganOx, founded in 2008 at the University of Oxford, specializes in organ preservation technology.
• The company developed the “Metra” device, approved in the US in 2021 and launched in 2022.
• Over 6,000 liver transplants have utilized OrganOx’s technology.
• The technology circulates oxygenated, nutrient-rich solution at body temperature for extended organ preservation.
• Terumo will acquire all shares from UK and French investment firms, making OrganOx a wholly owned subsidiary.
Summary
Terumo, a leading medical device company, announced its acquisition of UK-based OrganOx for $1.5 billion. OrganOx, established in 2008 at the University of Oxford, specializes in advanced organ preservation technology. Its flagship product, the “Metra” device, enables long-term organ storage by circulating oxygen and nutrients at body temperature, a significant improvement over traditional cooling methods. The device has been approved in the US since 2021 and has supported over 6,000 liver transplants. Terumo plans to finalize the acquisition by March 2026, pending regulatory approvals in the US and Europe. This move will make OrganOx a wholly owned subsidiary, strengthening Terumo’s position in the global organ transplantation market.
